Coya Therapeutics Finalizes Resale of 2.52M Shares by Selling Stockholders, Including Strategic Partner

summarizeSummary

Coya Therapeutics filed a prospectus for the resale of 2.52 million shares by selling stockholders, including Dr. Reddy's Laboratories, from a January private placement, with the company receiving no proceeds.

check_boxKey Events

• Resale of Shares Finalized

  A prospectus was filed for the resale of 2,522,727 shares of common stock by selling stockholders, making these shares available for sale in the market.

• No Proceeds to Company

  Coya Therapeutics will not receive any proceeds from the sale of these shares by the selling stockholders.

• Strategic Partner Selling Holdings

  Dr. Reddy's Laboratories, Inc., a key development partner, is selling all 2,272,727 shares it acquired in the January 29, 2026 private placement.

• Significant Market Overhang

  The shares available for resale represent a substantial portion of the company's market capitalization, potentially creating downward pressure on the stock.

auto_awesomeAnalysis

This 424B3 prospectus finalizes the terms for the resale of shares previously registered in an S-3 filing on March 16, 2026. The availability of 2.52 million shares for resale by selling stockholders, particularly the full exit of shares by strategic partner Dr. Reddy's Laboratories from the January private placement, creates a significant overhang on the stock. While the private placement itself provided capital to Coya Therapeutics, the current resale means the company receives no additional funds. The substantial volume of shares, representing over 11% of the market capitalization, could exert downward pressure on the stock price as these shares become freely tradable.